Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363727 · ClinicalTrials.gov registry record · Phase 3
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 209
- Enrollment target
NCT00363727 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 209 participants.
The verdict
NCT00363727, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 209 participants
- Enrollment target
Study Summary
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
Interventions
- DRUG ropinirole controlled-release (REQUIP CR) for RLS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363727
The ClinicalTrials.gov registry entry for NCT00363727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ropinirole controlled-release (REQUIP CR) for RLS is the first listed.
NCT00363727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363727 about?
NCT00363727 is a clinical study titled "Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's". This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
What is the current status of trial NCT00363727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 209 participants. The study started on 2003-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00363727?
The interventions under investigation include: ropinirole controlled-release (REQUIP CR) for RLS (DRUG).
Who is sponsoring clinical trial NCT00363727?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.